| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graft vs Host Disease | 258 | 2024 | 3044 | 13.570 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 250 | 2024 | 5713 | 9.940 |
Why?
|
| Transplantation Conditioning | 109 | 2024 | 1600 | 6.460 |
Why?
|
| Bone Marrow Transplantation | 119 | 2023 | 2709 | 5.330 |
Why?
|
| Transplantation, Homologous | 176 | 2024 | 4834 | 4.700 |
Why?
|
| Hematologic Neoplasms | 70 | 2024 | 1905 | 3.420 |
Why?
|
| Anemia, Aplastic | 21 | 2024 | 231 | 3.270 |
Why?
|
| Cord Blood Stem Cell Transplantation | 28 | 2020 | 305 | 3.260 |
Why?
|
| Myelodysplastic Syndromes | 47 | 2024 | 1399 | 3.130 |
Why?
|
| Sirolimus | 26 | 2020 | 1542 | 2.700 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 35 | 2018 | 687 | 2.660 |
Why?
|
| Immunosuppressive Agents | 51 | 2024 | 4209 | 2.480 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 18 | 2016 | 263 | 2.350 |
Why?
|
| Tacrolimus | 28 | 2023 | 750 | 2.140 |
Why?
|
| Leukemia, Myeloid, Acute | 38 | 2024 | 3620 | 2.080 |
Why?
|
| Leukemia | 38 | 2024 | 1526 | 2.030 |
Why?
|
| Hepatic Veno-Occlusive Disease | 18 | 2022 | 220 | 1.860 |
Why?
|
| Stem Cell Transplantation | 20 | 2020 | 1602 | 1.560 |
Why?
|
| Methotrexate | 24 | 2019 | 1722 | 1.460 |
Why?
|
| Iron Overload | 6 | 2014 | 246 | 1.420 |
Why?
|
| Antilymphocyte Serum | 11 | 2024 | 491 | 1.330 |
Why?
|
| Leukocyte Transfusion | 7 | 2006 | 56 | 1.290 |
Why?
|
| Disease-Free Survival | 68 | 2021 | 6856 | 1.180 |
Why?
|
| Tissue Donors | 39 | 2022 | 2389 | 1.100 |
Why?
|
| Myeloablative Agonists | 16 | 2018 | 210 | 1.100 |
Why?
|
| Fetal Blood | 14 | 2021 | 1361 | 1.040 |
Why?
|
| Histocompatibility Testing | 24 | 2019 | 716 | 1.030 |
Why?
|
| Interleukin-2 | 14 | 2022 | 1894 | 1.020 |
Why?
|
| Adult | 345 | 2024 | 223640 | 1.000 |
Why?
|
| Lymphoma | 17 | 2017 | 1907 | 0.980 |
Why?
|
| Recurrence | 63 | 2023 | 8506 | 0.960 |
Why?
|
| Cyclophosphamide | 25 | 2023 | 2226 | 0.950 |
Why?
|
| Graft vs Leukemia Effect | 10 | 2020 | 121 | 0.930 |
Why?
|
| Middle Aged | 313 | 2024 | 223491 | 0.900 |
Why?
|
| Polydeoxyribonucleotides | 9 | 2022 | 136 | 0.860 |
Why?
|
| Photopheresis | 2 | 2020 | 36 | 0.840 |
Why?
|
| Survival Analysis | 66 | 2019 | 10117 | 0.840 |
Why?
|
| HLA Antigens | 16 | 2021 | 1337 | 0.820 |
Why?
|
| Vidarabine | 15 | 2021 | 337 | 0.810 |
Why?
|
| alpha 1-Antitrypsin | 2 | 2020 | 169 | 0.790 |
Why?
|
| Bronchiolitis Obliterans | 9 | 2022 | 220 | 0.780 |
Why?
|
| T-Lymphocytes, Regulatory | 22 | 2022 | 3112 | 0.780 |
Why?
|
| Humans | 479 | 2024 | 768393 | 0.780 |
Why?
|
| Graft vs Tumor Effect | 7 | 2016 | 68 | 0.780 |
Why?
|
| Survival Rate | 60 | 2021 | 12870 | 0.770 |
Why?
|
| Acute Disease | 45 | 2021 | 7242 | 0.760 |
Why?
|
| Cyclosporine | 11 | 2019 | 779 | 0.720 |
Why?
|
| Hematologic Diseases | 10 | 2020 | 499 | 0.720 |
Why?
|
| Busulfan | 13 | 2021 | 259 | 0.720 |
Why?
|
| Male | 340 | 2024 | 364902 | 0.720 |
Why?
|
| Chronic Disease | 56 | 2023 | 9379 | 0.680 |
Why?
|
| Female | 332 | 2024 | 397089 | 0.680 |
Why?
|
| Histocompatibility | 19 | 2018 | 322 | 0.630 |
Why?
|
| Leukemia, Myeloid | 10 | 2021 | 693 | 0.610 |
Why?
|
| Aged | 184 | 2024 | 171562 | 0.600 |
Why?
|
| Adolescent | 141 | 2024 | 89184 | 0.590 |
Why?
|
| Lymphocyte Transfusion | 7 | 2024 | 232 | 0.590 |
Why?
|
| Transplantation Chimera | 11 | 2015 | 594 | 0.580 |
Why?
|
| Young Adult | 94 | 2024 | 60049 | 0.570 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 9 | 2017 | 1558 | 0.560 |
Why?
|
| Graft Survival | 28 | 2017 | 3900 | 0.550 |
Why?
|
| Sulfonamides | 2 | 2024 | 1980 | 0.550 |
Why?
|
| Cytomegalovirus Infections | 10 | 2023 | 839 | 0.550 |
Why?
|
| B-Lymphocytes | 20 | 2022 | 4785 | 0.550 |
Why?
|
| Adenine | 4 | 2021 | 993 | 0.540 |
Why?
|
| Treatment Outcome | 101 | 2021 | 65379 | 0.530 |
Why?
|
| Living Donors | 8 | 2015 | 651 | 0.520 |
Why?
|
| Piperidines | 4 | 2021 | 1659 | 0.520 |
Why?
|
| Graft Rejection | 11 | 2016 | 4505 | 0.520 |
Why?
|
| Stomatitis | 4 | 2016 | 271 | 0.490 |
Why?
|
| Ferritins | 5 | 2014 | 600 | 0.480 |
Why?
|
| Transplantation, Autologous | 25 | 2021 | 2127 | 0.470 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 9 | 2021 | 1643 | 0.470 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 5 | 2013 | 695 | 0.470 |
Why?
|
| Germinal Center | 4 | 2022 | 380 | 0.460 |
Why?
|
| Adrenal Cortex Hormones | 8 | 2020 | 1890 | 0.460 |
Why?
|
| Siblings | 12 | 2019 | 829 | 0.460 |
Why?
|
| Leukocytes, Mononuclear | 11 | 2016 | 1855 | 0.450 |
Why?
|
| Opportunistic Infections | 4 | 2023 | 375 | 0.450 |
Why?
|
| Combined Modality Therapy | 25 | 2021 | 8562 | 0.440 |
Why?
|
| Lymphocyte Depletion | 13 | 2016 | 605 | 0.440 |
Why?
|
| Mycophenolic Acid | 6 | 2019 | 350 | 0.440 |
Why?
|
| T-Lymphocytes | 25 | 2018 | 10267 | 0.440 |
Why?
|
| Multiple Organ Failure | 8 | 2018 | 387 | 0.410 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 4 | 2018 | 494 | 0.410 |
Why?
|
| Pyrazoles | 3 | 2020 | 2021 | 0.410 |
Why?
|
| Mouth Mucosa | 3 | 2014 | 437 | 0.400 |
Why?
|
| Hodgkin Disease | 10 | 2017 | 1386 | 0.400 |
Why?
|
| Mycoses | 4 | 2012 | 386 | 0.400 |
Why?
|
| Steroids | 11 | 2023 | 937 | 0.400 |
Why?
|
| Retrospective Studies | 97 | 2024 | 81801 | 0.400 |
Why?
|
| Donor Selection | 1 | 2014 | 240 | 0.400 |
Why?
|
| Blood Donors | 4 | 2017 | 344 | 0.390 |
Why?
|
| Chelation Therapy | 1 | 2012 | 77 | 0.390 |
Why?
|
| ABO Blood-Group System | 3 | 1999 | 381 | 0.390 |
Why?
|
| Neoplasms, Second Primary | 5 | 2023 | 1060 | 0.390 |
Why?
|
| B-Cell Activating Factor | 5 | 2014 | 116 | 0.390 |
Why?
|
| Lymphoma, Non-Hodgkin | 10 | 2017 | 1376 | 0.390 |
Why?
|
| Iron Chelating Agents | 1 | 2012 | 141 | 0.370 |
Why?
|
| Antifungal Agents | 3 | 2012 | 759 | 0.370 |
Why?
|
| Whole-Body Irradiation | 10 | 2023 | 435 | 0.360 |
Why?
|
| Hematopoietic Stem Cells | 8 | 2020 | 3407 | 0.360 |
Why?
|
| Drug Design | 1 | 2016 | 1046 | 0.360 |
Why?
|
| Sialoglycoproteins | 4 | 2005 | 320 | 0.360 |
Why?
|
| Pyrimidines | 8 | 2020 | 3048 | 0.350 |
Why?
|
| Immunotherapy, Adoptive | 8 | 2021 | 1508 | 0.350 |
Why?
|
| Sezary Syndrome | 1 | 2011 | 80 | 0.350 |
Why?
|
| Bone Marrow | 14 | 2020 | 2929 | 0.340 |
Why?
|
| BK Virus | 3 | 2020 | 120 | 0.340 |
Why?
|
| CD8-Positive T-Lymphocytes | 14 | 2022 | 4646 | 0.340 |
Why?
|
| Premedication | 3 | 2018 | 246 | 0.340 |
Why?
|
| Tandem Repeat Sequences | 3 | 2018 | 183 | 0.330 |
Why?
|
| Remission Induction | 17 | 2019 | 2407 | 0.330 |
Why?
|
| Blood Group Incompatibility | 3 | 2008 | 134 | 0.330 |
Why?
|
| Prednisone | 5 | 2020 | 1567 | 0.320 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2011 | 125 | 0.320 |
Why?
|
| Mycosis Fungoides | 1 | 2011 | 169 | 0.320 |
Why?
|
| Antibodies, Monoclonal | 18 | 2022 | 9261 | 0.320 |
Why?
|
| Lymphoma, B-Cell | 5 | 2019 | 945 | 0.320 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 24 | 2018 | 11854 | 0.320 |
Why?
|
| Myeloproliferative Disorders | 4 | 2016 | 613 | 0.310 |
Why?
|
| Clinical Trials as Topic | 9 | 2018 | 8051 | 0.310 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2013 | 507 | 0.310 |
Why?
|
| Antibodies | 3 | 2017 | 2425 | 0.300 |
Why?
|
| Quality of Life | 17 | 2024 | 13503 | 0.300 |
Why?
|
| Salvage Therapy | 7 | 2016 | 1277 | 0.300 |
Why?
|
| Prognosis | 41 | 2020 | 30022 | 0.300 |
Why?
|
| Transplantation Immunology | 7 | 2021 | 538 | 0.300 |
Why?
|
| Drug Resistance | 9 | 2020 | 1595 | 0.300 |
Why?
|
| Receptors, Interleukin-1 | 2 | 2002 | 260 | 0.300 |
Why?
|
| Parathyroid Hormone | 2 | 2012 | 1804 | 0.300 |
Why?
|
| Time Factors | 46 | 2021 | 40272 | 0.290 |
Why?
|
| Immunization | 5 | 2006 | 1219 | 0.290 |
Why?
|
| CD4-Positive T-Lymphocytes | 14 | 2020 | 4411 | 0.290 |
Why?
|
| Virus Activation | 4 | 2019 | 322 | 0.290 |
Why?
|
| Follow-Up Studies | 37 | 2020 | 39407 | 0.290 |
Why?
|
| Lymphoma, Follicular | 3 | 2022 | 460 | 0.280 |
Why?
|
| Antineoplastic Agents | 20 | 2018 | 13697 | 0.280 |
Why?
|
| Kaplan-Meier Estimate | 14 | 2021 | 6541 | 0.280 |
Why?
|
| T-Lymphocyte Subsets | 7 | 2019 | 1813 | 0.280 |
Why?
|
| Tumor Virus Infections | 4 | 2019 | 438 | 0.280 |
Why?
|
| Lymphocyte Activation | 13 | 2022 | 5496 | 0.280 |
Why?
|
| Interferon-alpha | 5 | 1999 | 910 | 0.270 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 8 | 2022 | 892 | 0.270 |
Why?
|
| Child | 68 | 2024 | 80891 | 0.270 |
Why?
|
| Antigens, CD34 | 4 | 2024 | 656 | 0.270 |
Why?
|
| Isoantibodies | 6 | 2011 | 682 | 0.270 |
Why?
|
| Polycythemia Vera | 2 | 2022 | 160 | 0.270 |
Why?
|
| Killer Cells, Natural | 10 | 2022 | 2206 | 0.270 |
Why?
|
| Nephrosis, Lipoid | 1 | 2006 | 45 | 0.270 |
Why?
|
| Iron | 3 | 2014 | 1814 | 0.260 |
Why?
|
| Mediastinal Neoplasms | 2 | 2019 | 403 | 0.250 |
Why?
|
| Child, Preschool | 53 | 2021 | 42650 | 0.250 |
Why?
|
| Fibrinolytic Agents | 6 | 2018 | 2074 | 0.250 |
Why?
|
| Cytomegalovirus | 6 | 2018 | 754 | 0.250 |
Why?
|
| Minor Histocompatibility Antigens | 5 | 2011 | 303 | 0.250 |
Why?
|
| Azacitidine | 2 | 2024 | 336 | 0.250 |
Why?
|
| Triazoles | 2 | 2012 | 904 | 0.250 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 6 | 2019 | 977 | 0.240 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 2005 | 106 | 0.240 |
Why?
|
| Polyomavirus Infections | 2 | 2019 | 192 | 0.240 |
Why?
|
| Immunocompromised Host | 4 | 2013 | 863 | 0.240 |
Why?
|
| Colony-Stimulating Factors | 3 | 1990 | 218 | 0.230 |
Why?
|
| Antibody Formation | 6 | 2017 | 1393 | 0.230 |
Why?
|
| Anemia, Sickle Cell | 4 | 2023 | 1065 | 0.230 |
Why?
|
| Pneumococcal Vaccines | 3 | 2005 | 414 | 0.230 |
Why?
|
| Immune System | 3 | 2009 | 801 | 0.230 |
Why?
|
| Incidence | 29 | 2023 | 21544 | 0.230 |
Why?
|
| Angiogenesis Inducing Agents | 2 | 2016 | 254 | 0.220 |
Why?
|
| Severity of Illness Index | 15 | 2020 | 15939 | 0.220 |
Why?
|
| Drug Evaluation | 7 | 2006 | 642 | 0.220 |
Why?
|
| Vulvar Diseases | 1 | 2003 | 64 | 0.210 |
Why?
|
| Diphtheria Toxin | 1 | 2004 | 253 | 0.210 |
Why?
|
| Growth Substances | 4 | 2001 | 761 | 0.210 |
Why?
|
| Niacinamide | 2 | 2016 | 418 | 0.210 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2016 | 5708 | 0.210 |
Why?
|
| Activated-Leukocyte Cell Adhesion Molecule | 1 | 2022 | 21 | 0.210 |
Why?
|
| Postoperative Complications | 7 | 2014 | 15881 | 0.210 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2023 | 617 | 0.210 |
Why?
|
| Prospective Studies | 33 | 2021 | 54920 | 0.210 |
Why?
|
| Treatment Failure | 4 | 2024 | 2663 | 0.210 |
Why?
|
| Vaginal Diseases | 1 | 2003 | 103 | 0.210 |
Why?
|
| Melphalan | 6 | 2020 | 421 | 0.210 |
Why?
|
| Lymphocytes | 6 | 2024 | 2611 | 0.200 |
Why?
|
| Phenylurea Compounds | 2 | 2016 | 530 | 0.200 |
Why?
|
| Telomerase | 2 | 2021 | 752 | 0.200 |
Why?
|
| Interleukin-11 | 1 | 2002 | 59 | 0.200 |
Why?
|
| Histiocytic Sarcoma | 1 | 2022 | 40 | 0.200 |
Why?
|
| HLA-C Antigens | 2 | 2016 | 146 | 0.200 |
Why?
|
| Depression | 6 | 2005 | 8241 | 0.200 |
Why?
|
| Gelsolin | 1 | 2002 | 189 | 0.190 |
Why?
|
| Dioxygenases | 2 | 2021 | 351 | 0.190 |
Why?
|
| Recombinant Proteins | 13 | 2013 | 6510 | 0.190 |
Why?
|
| Multiple Myeloma | 9 | 2019 | 5192 | 0.180 |
Why?
|
| Cytokines | 9 | 2021 | 7445 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 2 | 2018 | 190 | 0.180 |
Why?
|
| Antigens, Surface | 4 | 2017 | 1616 | 0.180 |
Why?
|
| Protein Kinases | 2 | 2004 | 1609 | 0.180 |
Why?
|
| Anemia, Sideroblastic | 1 | 2021 | 109 | 0.180 |
Why?
|
| Boronic Acids | 3 | 2014 | 915 | 0.180 |
Why?
|
| Follistatin | 2 | 2019 | 138 | 0.180 |
Why?
|
| Survivors | 4 | 2024 | 2382 | 0.170 |
Why?
|
| Sjogren's Syndrome | 1 | 2002 | 241 | 0.170 |
Why?
|
| Pneumocystis Infections | 1 | 2000 | 10 | 0.170 |
Why?
|
| Risk Factors | 38 | 2018 | 74962 | 0.170 |
Why?
|
| Pentamidine | 1 | 2000 | 44 | 0.170 |
Why?
|
| Minisatellite Repeats | 1 | 2001 | 164 | 0.170 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2021 | 167 | 0.170 |
Why?
|
| Lymphoproliferative Disorders | 6 | 2016 | 529 | 0.170 |
Why?
|
| Janus Kinase 1 | 1 | 2020 | 107 | 0.170 |
Why?
|
| Limbic Encephalitis | 2 | 2012 | 36 | 0.170 |
Why?
|
| Cryopreservation | 5 | 2021 | 733 | 0.170 |
Why?
|
| Antigens, CD | 10 | 2022 | 4031 | 0.170 |
Why?
|
| Mouth Neoplasms | 2 | 2018 | 597 | 0.170 |
Why?
|
| Cohort Studies | 28 | 2018 | 41795 | 0.170 |
Why?
|
| Recovery of Function | 4 | 2019 | 2990 | 0.170 |
Why?
|
| Leukemia, Experimental | 1 | 2020 | 225 | 0.170 |
Why?
|
| Bone Marrow Cells | 9 | 2005 | 2414 | 0.160 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2023 | 271 | 0.160 |
Why?
|
| Janus Kinase 2 | 2 | 2020 | 560 | 0.160 |
Why?
|
| Herpesvirus 6, Human | 2 | 2012 | 98 | 0.160 |
Why?
|
| Vaccination | 5 | 2022 | 3431 | 0.160 |
Why?
|
| Receptors, CXCR5 | 2 | 2016 | 88 | 0.160 |
Why?
|
| Mutation | 10 | 2021 | 30228 | 0.160 |
Why?
|
| Endothelium, Vascular | 2 | 2010 | 4427 | 0.160 |
Why?
|
| Pyrazines | 3 | 2014 | 1206 | 0.160 |
Why?
|
| Multivariate Analysis | 16 | 2017 | 12092 | 0.150 |
Why?
|
| Age Factors | 19 | 2024 | 18471 | 0.150 |
Why?
|
| Interferon Regulatory Factor-7 | 1 | 2018 | 36 | 0.150 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 1998 | 27 | 0.150 |
Why?
|
| Disease Management | 5 | 2021 | 2537 | 0.150 |
Why?
|
| Polyradiculoneuropathy | 1 | 1997 | 65 | 0.150 |
Why?
|
| Animals | 30 | 2024 | 169337 | 0.150 |
Why?
|
| Meningococcal Vaccines | 1 | 2018 | 96 | 0.150 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2021 | 656 | 0.140 |
Why?
|
| Gene Deletion | 2 | 2019 | 2673 | 0.140 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2018 | 86 | 0.140 |
Why?
|
| Hematopoiesis | 7 | 2021 | 2058 | 0.140 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2020 | 434 | 0.140 |
Why?
|
| Haemophilus Vaccines | 5 | 1998 | 71 | 0.140 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 2 | 2016 | 306 | 0.140 |
Why?
|
| Drug Therapy, Combination | 9 | 2016 | 6318 | 0.140 |
Why?
|
| Clofazimine | 1 | 1997 | 41 | 0.140 |
Why?
|
| Interleukin-15 | 1 | 2018 | 185 | 0.140 |
Why?
|
| Rho(D) Immune Globulin | 1 | 1997 | 34 | 0.140 |
Why?
|
| Adaptation, Psychological | 4 | 2005 | 2663 | 0.140 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2011 | 3731 | 0.140 |
Why?
|
| Graft vs Host Reaction | 1 | 1997 | 99 | 0.140 |
Why?
|
| Neutropenia | 2 | 1992 | 893 | 0.140 |
Why?
|
| Infant | 26 | 2021 | 36510 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 3 | 2016 | 225 | 0.140 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2018 | 124 | 0.140 |
Why?
|
| Clone Cells | 2 | 2017 | 1671 | 0.140 |
Why?
|
| Standard of Care | 1 | 2021 | 570 | 0.130 |
Why?
|
| Blood Specimen Collection | 2 | 2016 | 238 | 0.130 |
Why?
|
| Immunomodulation | 1 | 2020 | 549 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2023 | 9433 | 0.130 |
Why?
|
| Leukocyte Count | 7 | 2019 | 1605 | 0.130 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2020 | 677 | 0.130 |
Why?
|
| Glutamine | 3 | 1998 | 578 | 0.130 |
Why?
|
| Cancer Vaccines | 3 | 2014 | 1042 | 0.130 |
Why?
|
| Risk Adjustment | 1 | 2000 | 603 | 0.130 |
Why?
|
| Regeneration | 1 | 2005 | 1525 | 0.130 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 4 | 2016 | 631 | 0.130 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2021 | 1428 | 0.130 |
Why?
|
| Mouth Diseases | 2 | 2016 | 239 | 0.130 |
Why?
|
| Vaccines, Attenuated | 2 | 2013 | 314 | 0.120 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2016 | 289 | 0.120 |
Why?
|
| Pneumonia | 2 | 2008 | 2163 | 0.120 |
Why?
|
| Proteins | 4 | 2022 | 6006 | 0.120 |
Why?
|
| Piperazines | 4 | 2008 | 2552 | 0.120 |
Why?
|
| Stem Cell Factor | 1 | 2015 | 194 | 0.120 |
Why?
|
| Mental Health | 1 | 2009 | 3276 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2013 | 10776 | 0.120 |
Why?
|
| Interleukin-7 | 1 | 2015 | 145 | 0.120 |
Why?
|
| Lymphocyte Count | 5 | 2019 | 793 | 0.120 |
Why?
|
| Immunologic Memory | 3 | 2017 | 1374 | 0.120 |
Why?
|
| Nitriles | 1 | 2020 | 984 | 0.120 |
Why?
|
| Leukemia, Biphenotypic, Acute | 1 | 2014 | 32 | 0.120 |
Why?
|
| H-Y Antigen | 2 | 2004 | 42 | 0.120 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2016 | 147 | 0.120 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 906 | 0.120 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 3 | 2002 | 299 | 0.120 |
Why?
|
| Telomere | 1 | 2020 | 943 | 0.120 |
Why?
|
| Immunoglobulin G | 9 | 2011 | 4570 | 0.120 |
Why?
|
| Epidermal Growth Factor | 1 | 2017 | 698 | 0.120 |
Why?
|
| Skin Diseases | 4 | 2019 | 1084 | 0.110 |
Why?
|
| Thrombomodulin | 2 | 2016 | 107 | 0.110 |
Why?
|
| rho-Associated Kinases | 1 | 2016 | 286 | 0.110 |
Why?
|
| Primary Myelofibrosis | 2 | 2013 | 209 | 0.110 |
Why?
|
| Antibody Specificity | 3 | 2011 | 1065 | 0.110 |
Why?
|
| Parenteral Nutrition | 3 | 1998 | 663 | 0.110 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 1794 | 0.110 |
Why?
|
| Infusions, Intravenous | 4 | 2012 | 2226 | 0.110 |
Why?
|
| Vaccines, Conjugate | 5 | 2005 | 334 | 0.110 |
Why?
|
| 16,16-Dimethylprostaglandin E2 | 1 | 2013 | 22 | 0.110 |
Why?
|
| Bradyrhizobium | 1 | 2013 | 16 | 0.110 |
Why?
|
| Colitis | 2 | 2013 | 1244 | 0.110 |
Why?
|
| Adoptive Transfer | 1 | 2016 | 824 | 0.110 |
Why?
|
| Genetic Variation | 3 | 2021 | 6606 | 0.110 |
Why?
|
| Evidence-Based Medicine | 2 | 2024 | 3707 | 0.110 |
Why?
|
| Attitude to Health | 2 | 2003 | 2025 | 0.110 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2016 | 648 | 0.110 |
Why?
|
| Ricin | 2 | 1990 | 70 | 0.110 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2013 | 49 | 0.110 |
Why?
|
| Health Behavior | 1 | 2005 | 2647 | 0.110 |
Why?
|
| Pain | 3 | 2005 | 5103 | 0.110 |
Why?
|
| Tongue | 1 | 1996 | 406 | 0.100 |
Why?
|
| Small Molecule Libraries | 1 | 2018 | 742 | 0.100 |
Why?
|
| Etoposide | 4 | 2001 | 639 | 0.100 |
Why?
|
| Data Collection | 7 | 2011 | 3324 | 0.100 |
Why?
|
| Vaccinia | 1 | 2013 | 71 | 0.100 |
Why?
|
| Benzamides | 4 | 2008 | 1380 | 0.100 |
Why?
|
| Adenoviridae Infections | 1 | 2013 | 96 | 0.100 |
Why?
|
| Dyskeratosis Congenita | 1 | 2013 | 70 | 0.100 |
Why?
|
| Chromosome Aberrations | 1 | 2019 | 1780 | 0.100 |
Why?
|
| Immunotoxins | 2 | 1990 | 175 | 0.100 |
Why?
|
| Receptors, KIR | 1 | 2013 | 114 | 0.100 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 1088 | 0.100 |
Why?
|
| Smallpox Vaccine | 1 | 2013 | 77 | 0.100 |
Why?
|
| Infusions, Subcutaneous | 1 | 2012 | 43 | 0.100 |
Why?
|
| Clinical Protocols | 2 | 2018 | 1445 | 0.100 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 1997 | 246 | 0.100 |
Why?
|
| Spleen | 3 | 2016 | 2296 | 0.100 |
Why?
|
| Syndrome | 5 | 2018 | 3275 | 0.100 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 5 | 2022 | 896 | 0.100 |
Why?
|
| Herpesvirus 4, Human | 4 | 2023 | 1082 | 0.100 |
Why?
|
| Viremia | 2 | 2019 | 725 | 0.100 |
Why?
|
| Registries | 11 | 2019 | 8379 | 0.100 |
Why?
|
| Decision Support Techniques | 2 | 2004 | 2006 | 0.100 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2012 | 70 | 0.100 |
Why?
|
| DEAD-box RNA Helicases | 3 | 2011 | 384 | 0.100 |
Why?
|
| Flow Cytometry | 9 | 2015 | 5900 | 0.100 |
Why?
|
| Philadelphia Chromosome | 3 | 2010 | 119 | 0.100 |
Why?
|
| Pilot Projects | 6 | 2024 | 8731 | 0.100 |
Why?
|
| Roseolovirus Infections | 1 | 2012 | 50 | 0.100 |
Why?
|
| Disease Progression | 8 | 2016 | 13646 | 0.100 |
Why?
|
| Alcohol Drinking | 1 | 2005 | 4049 | 0.100 |
Why?
|
| Bone Marrow Purging | 1 | 1991 | 108 | 0.100 |
Why?
|
| Mutagenesis, Insertional | 1 | 2014 | 662 | 0.100 |
Why?
|
| Deferoxamine | 1 | 2012 | 155 | 0.100 |
Why?
|
| Topography, Medical | 1 | 2011 | 37 | 0.100 |
Why?
|
| Oral Health | 1 | 2017 | 493 | 0.100 |
Why?
|
| STAT3 Transcription Factor | 1 | 2016 | 875 | 0.100 |
Why?
|
| Adjuvants, Immunologic | 1 | 1997 | 998 | 0.100 |
Why?
|
| Antibodies, Viral | 6 | 2019 | 3211 | 0.100 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2014 | 640 | 0.090 |
Why?
|
| Homeostasis | 3 | 2013 | 3349 | 0.090 |
Why?
|
| Pyridones | 1 | 2017 | 818 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 5 | 2020 | 6234 | 0.090 |
Why?
|
| Placebos | 3 | 2014 | 1668 | 0.090 |
Why?
|
| Receptors, Complement | 1 | 1992 | 254 | 0.090 |
Why?
|
| Splenomegaly | 1 | 2012 | 192 | 0.090 |
Why?
|
| Patient Readmission | 2 | 2016 | 3312 | 0.090 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 1019 | 0.090 |
Why?
|
| Vaccinia virus | 1 | 2013 | 330 | 0.090 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2022 | 2676 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2011 | 5857 | 0.090 |
Why?
|
| Chromosomes, Human, Y | 2 | 2010 | 163 | 0.090 |
Why?
|
| Carmustine | 4 | 2001 | 137 | 0.090 |
Why?
|
| Antibodies, Bacterial | 4 | 2005 | 1478 | 0.090 |
Why?
|
| Dexamethasone | 2 | 2016 | 1965 | 0.090 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 1748 | 0.090 |
Why?
|
| Analysis of Variance | 6 | 2012 | 6241 | 0.090 |
Why?
|
| Neoplasms | 14 | 2018 | 22385 | 0.090 |
Why?
|
| Fusion Proteins, bcr-abl | 3 | 2006 | 430 | 0.090 |
Why?
|
| Genotype | 5 | 2021 | 13042 | 0.090 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 2038 | 0.090 |
Why?
|
| Thrombocythemia, Essential | 1 | 2012 | 114 | 0.090 |
Why?
|
| STAT5 Transcription Factor | 3 | 2017 | 268 | 0.090 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2014 | 618 | 0.090 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 1943 | 0.090 |
Why?
|
| Comorbidity | 5 | 2019 | 10588 | 0.090 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2010 | 109 | 0.090 |
Why?
|
| Tetanus Toxoid | 4 | 1998 | 189 | 0.090 |
Why?
|
| Statistics, Nonparametric | 5 | 2017 | 2862 | 0.090 |
Why?
|
| Bacteremia | 1 | 2017 | 985 | 0.090 |
Why?
|
| Epithelium | 2 | 2011 | 1609 | 0.090 |
Why?
|
| DNA-Binding Proteins | 3 | 2021 | 9614 | 0.090 |
Why?
|
| Cost of Illness | 1 | 2020 | 1959 | 0.090 |
Why?
|
| Proportional Hazards Models | 12 | 2015 | 12558 | 0.080 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 1207 | 0.080 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2011 | 168 | 0.080 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2010 | 123 | 0.080 |
Why?
|
| Leukocytes | 2 | 2014 | 2030 | 0.080 |
Why?
|
| Lymphocyte Subsets | 2 | 2009 | 313 | 0.080 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2010 | 246 | 0.080 |
Why?
|
| Case-Control Studies | 10 | 2014 | 22296 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 9 | 2020 | 22355 | 0.080 |
Why?
|
| Cytogenetics | 2 | 2007 | 198 | 0.080 |
Why?
|
| Chimera | 3 | 2001 | 454 | 0.080 |
Why?
|
| Spinal Cord Diseases | 1 | 1992 | 293 | 0.080 |
Why?
|
| Diarrhea | 3 | 2013 | 1320 | 0.080 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2013 | 1795 | 0.080 |
Why?
|
| Thymus Gland | 3 | 2010 | 1266 | 0.080 |
Why?
|
| Cytarabine | 3 | 1999 | 697 | 0.080 |
Why?
|
| Transplantation | 1 | 2011 | 221 | 0.080 |
Why?
|
| Erythema | 1 | 2010 | 261 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 3610 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 2003 | 0.080 |
Why?
|
| Herpes Simplex | 1 | 1992 | 470 | 0.080 |
Why?
|
| Calcineurin | 2 | 2008 | 236 | 0.080 |
Why?
|
| Gene Expression | 5 | 2016 | 7598 | 0.080 |
Why?
|
| Erythroblasts | 2 | 2007 | 142 | 0.080 |
Why?
|
| Health Status Indicators | 1 | 2014 | 971 | 0.080 |
Why?
|
| Haplotypes | 2 | 2014 | 2724 | 0.080 |
Why?
|
| Smoking | 3 | 2004 | 9111 | 0.080 |
Why?
|
| Enzyme Inhibitors | 3 | 2022 | 3722 | 0.080 |
Why?
|
| Major Histocompatibility Complex | 2 | 2009 | 877 | 0.080 |
Why?
|
| Bronchi | 1 | 2012 | 849 | 0.080 |
Why?
|
| United States | 13 | 2024 | 73150 | 0.080 |
Why?
|
| Patient Selection | 1 | 2020 | 4266 | 0.080 |
Why?
|
| Satiety Response | 3 | 1978 | 47 | 0.080 |
Why?
|
| Satiation | 4 | 1978 | 84 | 0.080 |
Why?
|
| Hypertriglyceridemia | 1 | 2011 | 293 | 0.080 |
Why?
|
| Drug Interactions | 2 | 2019 | 1420 | 0.080 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2010 | 353 | 0.080 |
Why?
|
| Hemolysis | 2 | 2007 | 418 | 0.080 |
Why?
|
| Aminoglycosides | 2 | 2012 | 161 | 0.080 |
Why?
|
| Radiography, Thoracic | 1 | 2015 | 1320 | 0.080 |
Why?
|
| Kidney | 2 | 2018 | 7064 | 0.070 |
Why?
|
| Cholecystokinin | 3 | 1978 | 115 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 5 | 2013 | 6085 | 0.070 |
Why?
|
| E-Selectin | 1 | 2010 | 578 | 0.070 |
Why?
|
| Pulmonary Edema | 1 | 2010 | 409 | 0.070 |
Why?
|
| Neutrophils | 4 | 2016 | 3785 | 0.070 |
Why?
|
| Phenotype | 6 | 2021 | 16721 | 0.070 |
Why?
|
| Haemophilus influenzae | 2 | 1998 | 177 | 0.070 |
Why?
|
| Breast Implants | 1 | 2011 | 414 | 0.070 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2009 | 241 | 0.070 |
Why?
|
| Karnofsky Performance Status | 2 | 2011 | 167 | 0.070 |
Why?
|
| Fever | 2 | 2016 | 1620 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2022 | 2524 | 0.070 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2011 | 594 | 0.070 |
Why?
|
| Inflammation | 3 | 2009 | 10863 | 0.070 |
Why?
|
| Eye Diseases | 1 | 2013 | 657 | 0.070 |
Why?
|
| Lymphokines | 2 | 1991 | 927 | 0.070 |
Why?
|
| Haemophilus Infections | 2 | 1998 | 94 | 0.070 |
Why?
|
| Risk | 10 | 2013 | 9636 | 0.070 |
Why?
|
| Oral Ulcer | 1 | 2008 | 96 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1997 | 2276 | 0.070 |
Why?
|
| Cause of Death | 6 | 2021 | 3728 | 0.070 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2016 | 1077 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 4 | 2015 | 2475 | 0.070 |
Why?
|
| Family | 1 | 1998 | 3208 | 0.070 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2007 | 65 | 0.070 |
Why?
|
| North America | 1 | 2010 | 1290 | 0.070 |
Why?
|
| Databases, Factual | 4 | 2018 | 8075 | 0.070 |
Why?
|
| Hypolipidemic Agents | 1 | 2011 | 609 | 0.070 |
Why?
|
| Length of Stay | 4 | 2015 | 6519 | 0.070 |
Why?
|
| Boston | 4 | 2020 | 9371 | 0.070 |
Why?
|
| Receptors, Interleukin-2 | 2 | 2005 | 564 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell | 4 | 2019 | 2568 | 0.070 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2010 | 450 | 0.070 |
Why?
|
| Erythroid Cells | 1 | 2008 | 238 | 0.070 |
Why?
|
| Health Care Costs | 1 | 2000 | 3267 | 0.070 |
Why?
|
| Melanoma | 1 | 2005 | 5705 | 0.070 |
Why?
|
| Liver | 3 | 2012 | 7574 | 0.070 |
Why?
|
| Mice | 13 | 2022 | 82017 | 0.070 |
Why?
|
| Brain Diseases | 1 | 1995 | 1552 | 0.070 |
Why?
|
| Immunity, Humoral | 1 | 2010 | 611 | 0.070 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2010 | 827 | 0.070 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2010 | 1133 | 0.070 |
Why?
|
| Translocation, Genetic | 2 | 2011 | 1395 | 0.060 |
Why?
|
| Drug Monitoring | 1 | 2012 | 964 | 0.060 |
Why?
|
| von Willebrand Factor | 1 | 2010 | 680 | 0.060 |
Why?
|
| Bacteria | 1 | 2017 | 2221 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 588 | 0.060 |
Why?
|
| Dendritic Cells | 2 | 2014 | 2749 | 0.060 |
Why?
|
| beta-Thalassemia | 1 | 2008 | 236 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 2433 | 0.060 |
Why?
|
| Risk Assessment | 8 | 2019 | 24318 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2017 | 1409 | 0.060 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2009 | 1362 | 0.060 |
Why?
|
| Models, Statistical | 3 | 2012 | 5099 | 0.060 |
Why?
|
| Regression Analysis | 5 | 2000 | 6350 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2017 | 4526 | 0.060 |
Why?
|
| Mice, Knockout | 5 | 2020 | 14481 | 0.060 |
Why?
|
| Mouth | 2 | 2008 | 383 | 0.060 |
Why?
|
| Alleles | 5 | 2021 | 6892 | 0.060 |
Why?
|
| Herpesviridae Infections | 2 | 1999 | 269 | 0.060 |
Why?
|
| Erythropoiesis | 2 | 2008 | 693 | 0.060 |
Why?
|
| Colon | 1 | 2013 | 1805 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 2014 | 1597 | 0.060 |
Why?
|
| Blood Platelets | 2 | 2013 | 2476 | 0.060 |
Why?
|
| Drug Administration Schedule | 6 | 2017 | 4859 | 0.060 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2017 | 2763 | 0.060 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 1985 | 96 | 0.060 |
Why?
|
| Internationality | 1 | 2010 | 1008 | 0.060 |
Why?
|
| Biological Specimen Banks | 1 | 2010 | 784 | 0.060 |
Why?
|
| Mice, Mutant Strains | 2 | 2019 | 1755 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 2890 | 0.060 |
Why?
|
| Endothelial Cells | 2 | 2010 | 3587 | 0.060 |
Why?
|
| Integrins | 1 | 2009 | 843 | 0.060 |
Why?
|
| Serologic Tests | 1 | 2007 | 383 | 0.060 |
Why?
|
| Intestinal Diseases | 1 | 2009 | 505 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2014 | 10377 | 0.060 |
Why?
|
| Hypercholesterolemia | 1 | 2011 | 1142 | 0.060 |
Why?
|
| Cognition | 2 | 2014 | 7075 | 0.060 |
Why?
|
| Immunophenotyping | 3 | 2016 | 1866 | 0.060 |
Why?
|
| Albumins | 1 | 2007 | 577 | 0.060 |
Why?
|
| Receptors, Cell Surface | 1 | 2013 | 2819 | 0.060 |
Why?
|
| Thalidomide | 2 | 2011 | 886 | 0.060 |
Why?
|
| Self-Assessment | 1 | 2006 | 401 | 0.060 |
Why?
|
| Venous Thromboembolism | 1 | 2017 | 1881 | 0.060 |
Why?
|
| Rabbits | 1 | 2010 | 4781 | 0.050 |
Why?
|
| Chemokines | 1 | 2008 | 962 | 0.050 |
Why?
|
| Polymorphism, Genetic | 4 | 2009 | 4250 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2016 | 2596 | 0.050 |
Why?
|
| Aging | 4 | 2010 | 8764 | 0.050 |
Why?
|
| Sensitivity and Specificity | 6 | 2016 | 14737 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2000 | 2931 | 0.050 |
Why?
|
| Aged, 80 and over | 11 | 2020 | 59686 | 0.050 |
Why?
|
| Erythropoietin | 3 | 1994 | 719 | 0.050 |
Why?
|
| Influenza Vaccines | 1 | 2010 | 780 | 0.050 |
Why?
|
| Pneumococcal Infections | 2 | 2005 | 529 | 0.050 |
Why?
|
| Infant, Newborn | 7 | 2021 | 26411 | 0.050 |
Why?
|
| Blood Grouping and Crossmatching | 2 | 1998 | 99 | 0.050 |
Why?
|
| Double-Blind Method | 7 | 2013 | 12456 | 0.050 |
Why?
|
| Drug Compounding | 1 | 2003 | 243 | 0.050 |
Why?
|
| Predictive Value of Tests | 5 | 2020 | 15455 | 0.050 |
Why?
|
| Fetal Proteins | 1 | 2022 | 99 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2012 | 5313 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 4 | 2017 | 4775 | 0.050 |
Why?
|
| Cell Proliferation | 4 | 2019 | 10478 | 0.050 |
Why?
|
| Genomics | 1 | 2018 | 5916 | 0.050 |
Why?
|
| Histiocytes | 1 | 2022 | 97 | 0.050 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 1994 | 249 | 0.050 |
Why?
|
| Macrophages | 1 | 2017 | 5796 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2012 | 36849 | 0.050 |
Why?
|
| Neoplasm Staging | 5 | 2020 | 11254 | 0.050 |
Why?
|
| Drug Dosage Calculations | 2 | 2012 | 117 | 0.050 |
Why?
|
| Administration, Topical | 1 | 2003 | 703 | 0.050 |
Why?
|
| Affect | 1 | 2009 | 1501 | 0.050 |
Why?
|
| Diterpenes | 1 | 2022 | 170 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2014 | 5151 | 0.050 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2002 | 130 | 0.050 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 2001 | 767 | 0.050 |
Why?
|
| Disease Models, Animal | 5 | 2020 | 18362 | 0.050 |
Why?
|
| Platelet Count | 3 | 2017 | 784 | 0.050 |
Why?
|
| Immune Tolerance | 3 | 2019 | 2324 | 0.050 |
Why?
|
| Antigens, Neoplasm | 3 | 1999 | 1999 | 0.050 |
Why?
|
| Heparin | 2 | 1998 | 1636 | 0.050 |
Why?
|
| Psychomotor Performance | 1 | 2009 | 1895 | 0.050 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2022 | 263 | 0.050 |
Why?
|
| Mitochondria | 1 | 2014 | 3675 | 0.040 |
Why?
|
| Forehead | 1 | 2021 | 75 | 0.040 |
Why?
|
| Pulmonary Fibrosis | 2 | 2017 | 506 | 0.040 |
Why?
|
| Blood Transfusion | 3 | 2020 | 1309 | 0.040 |
Why?
|
| Leukoplakia | 1 | 2020 | 18 | 0.040 |
Why?
|
| Vital Capacity | 2 | 2014 | 984 | 0.040 |
Why?
|
| Creatinine | 1 | 2006 | 1915 | 0.040 |
Why?
|
| Aerosol Propellants | 1 | 2000 | 8 | 0.040 |
Why?
|
| Paris | 1 | 2020 | 41 | 0.040 |
Why?
|
| Ohio | 1 | 2021 | 328 | 0.040 |
Why?
|
| Sulfamethoxazole | 1 | 2000 | 51 | 0.040 |
Why?
|
| Body Fluids | 1 | 2002 | 322 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2016 | 1339 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2019 | 16028 | 0.040 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 1999 | 38 | 0.040 |
Why?
|
| Trimethoprim | 1 | 2000 | 79 | 0.040 |
Why?
|
| Hyaluronic Acid | 1 | 2003 | 487 | 0.040 |
Why?
|
| Receptors, Complement 3b | 2 | 2007 | 136 | 0.040 |
Why?
|
| Endocrine System Diseases | 1 | 2002 | 250 | 0.040 |
Why?
|
| Karyotyping | 2 | 2012 | 1173 | 0.040 |
Why?
|
| Lung Diseases | 2 | 2019 | 1925 | 0.040 |
Why?
|
| Dapsone | 1 | 2000 | 55 | 0.040 |
Why?
|
| Memory | 1 | 2009 | 2210 | 0.040 |
Why?
|
| Cell Count | 3 | 2016 | 1833 | 0.040 |
Why?
|
| Activities of Daily Living | 3 | 2005 | 2433 | 0.040 |
Why?
|
| ROC Curve | 2 | 2016 | 3623 | 0.040 |
Why?
|
| Models, Econometric | 1 | 2000 | 215 | 0.040 |
Why?
|
| Influenza, Human | 1 | 2010 | 1539 | 0.040 |
Why?
|
| Dermatologic Agents | 1 | 2003 | 312 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2011 | 3078 | 0.040 |
Why?
|
| Immunoblotting | 1 | 2002 | 1647 | 0.040 |
Why?
|
| Cells, Cultured | 6 | 2016 | 19022 | 0.040 |
Why?
|
| Myocardium | 1 | 2012 | 4788 | 0.040 |
Why?
|
| Attention | 1 | 2009 | 2425 | 0.040 |
Why?
|
| Models, Immunological | 1 | 2001 | 518 | 0.040 |
Why?
|
| Transcription, Genetic | 2 | 1992 | 7599 | 0.040 |
Why?
|
| Blood Cells | 1 | 2001 | 308 | 0.040 |
Why?
|
| Markov Chains | 2 | 2004 | 977 | 0.040 |
Why?
|
| Crohn Disease | 1 | 2011 | 2293 | 0.040 |
Why?
|
| Tetanus | 1 | 1998 | 52 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2004 | 2066 | 0.040 |
Why?
|
| Injections, Intravenous | 2 | 2000 | 1379 | 0.040 |
Why?
|
| Models, Biological | 1 | 2015 | 9493 | 0.040 |
Why?
|
| Granulocytes | 2 | 1992 | 550 | 0.040 |
Why?
|
| Benzoates | 1 | 2020 | 213 | 0.040 |
Why?
|
| Scleroderma, Localized | 1 | 2019 | 85 | 0.040 |
Why?
|
| DNA Mutational Analysis | 2 | 2017 | 4120 | 0.040 |
Why?
|
| Hydrazines | 1 | 2020 | 223 | 0.040 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2001 | 549 | 0.040 |
Why?
|
| Fetus | 1 | 1986 | 1883 | 0.040 |
Why?
|
| Biomedical Research | 2 | 2011 | 3464 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2005 | 4047 | 0.040 |
Why?
|
| Forced Expiratory Volume | 2 | 2014 | 1820 | 0.040 |
Why?
|
| Substance-Related Disorders | 2 | 2010 | 4429 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2002 | 632 | 0.040 |
Why?
|
| HLA-DR Antigens | 2 | 1993 | 607 | 0.040 |
Why?
|
| Thrombopoietin | 1 | 2000 | 226 | 0.040 |
Why?
|
| Databases as Topic | 1 | 2000 | 475 | 0.040 |
Why?
|
| Wounds and Injuries | 1 | 2011 | 2514 | 0.040 |
Why?
|
| Interferons | 1 | 2001 | 716 | 0.040 |
Why?
|
| Biopsy | 5 | 2013 | 6808 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 3 | 2011 | 1623 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 1985 | 1356 | 0.040 |
Why?
|
| Cell Separation | 2 | 2016 | 1726 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2018 | 8634 | 0.040 |
Why?
|
| Massachusetts | 2 | 2021 | 8902 | 0.040 |
Why?
|
| Immunization Schedule | 1 | 1998 | 228 | 0.040 |
Why?
|
| Apoptosis | 4 | 2014 | 9516 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2019 | 3520 | 0.030 |
Why?
|
| Retreatment | 1 | 1999 | 600 | 0.030 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2002 | 640 | 0.030 |
Why?
|
| Genetic Markers | 2 | 2017 | 2604 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1986 | 2202 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 890 | 0.030 |
Why?
|
| Estrogens | 1 | 2003 | 1534 | 0.030 |
Why?
|
| Safety | 2 | 1999 | 1159 | 0.030 |
Why?
|
| Cell Lineage | 2 | 2008 | 2574 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2001 | 669 | 0.030 |
Why?
|
| Pain Measurement | 2 | 2008 | 3581 | 0.030 |
Why?
|
| Leukopenia | 1 | 2017 | 212 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2000 | 1169 | 0.030 |
Why?
|
| Sample Size | 1 | 2020 | 848 | 0.030 |
Why?
|
| Progesterone | 1 | 2021 | 751 | 0.030 |
Why?
|
| Mediastinum | 1 | 1998 | 272 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 3813 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 3252 | 0.030 |
Why?
|
| Lymphocyte Cooperation | 1 | 2016 | 112 | 0.030 |
Why?
|
| Hypertension | 2 | 1998 | 8615 | 0.030 |
Why?
|
| Angiopoietin-1 | 1 | 2016 | 122 | 0.030 |
Why?
|
| Fatigue | 1 | 2003 | 1555 | 0.030 |
Why?
|
| Costs and Cost Analysis | 3 | 2008 | 1669 | 0.030 |
Why?
|
| Colonic Diseases | 1 | 1998 | 203 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2007 | 2784 | 0.030 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 2 | 1987 | 317 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 2009 | 3736 | 0.030 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2016 | 220 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1999 | 646 | 0.030 |
Why?
|
| Blood Component Removal | 1 | 1997 | 132 | 0.030 |
Why?
|
| Angiopoietin-2 | 1 | 2016 | 173 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 3 | 1998 | 1629 | 0.030 |
Why?
|
| Glucocorticoids | 2 | 2018 | 2168 | 0.030 |
Why?
|
| Cognition Disorders | 1 | 2009 | 3985 | 0.030 |
Why?
|
| Headache | 1 | 2003 | 1262 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 4069 | 0.030 |
Why?
|
| Actuarial Analysis | 2 | 1997 | 372 | 0.030 |
Why?
|
| Lymphopoiesis | 1 | 2016 | 133 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2017 | 874 | 0.030 |
Why?
|
| Nitrogen | 2 | 1997 | 345 | 0.030 |
Why?
|
| Blood Cell Count | 3 | 1997 | 402 | 0.030 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2016 | 151 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2002 | 1076 | 0.030 |
Why?
|
| Lipids | 1 | 2006 | 3344 | 0.030 |
Why?
|
| Daunorubicin | 1 | 1995 | 157 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2012 | 20765 | 0.030 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2021 | 954 | 0.030 |
Why?
|
| Receptors, Interleukin-21 | 1 | 2014 | 32 | 0.030 |
Why?
|
| Stress, Psychological | 3 | 2009 | 4543 | 0.030 |
Why?
|
| Drug Synergism | 2 | 2012 | 1762 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2005 | 2635 | 0.030 |
Why?
|
| Cell Division | 4 | 2004 | 4479 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2017 | 716 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2017 | 606 | 0.030 |
Why?
|
| Anemia, Hemolytic | 1 | 1995 | 164 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2020 | 839 | 0.030 |
Why?
|
| Cell Differentiation | 3 | 2007 | 11668 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2000 | 1195 | 0.030 |
Why?
|
| Transplants | 1 | 2016 | 208 | 0.030 |
Why?
|
| Gene Frequency | 3 | 2008 | 3617 | 0.030 |
Why?
|
| Sex Factors | 4 | 2011 | 10654 | 0.030 |
Why?
|
| Nuclear Family | 3 | 2002 | 311 | 0.030 |
Why?
|
| Models, Psychological | 1 | 1998 | 828 | 0.030 |
Why?
|
| Methods | 2 | 2005 | 1067 | 0.030 |
Why?
|
| Longitudinal Studies | 4 | 2014 | 14784 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2006 | 2491 | 0.030 |
Why?
|
| Health Resources | 1 | 2020 | 950 | 0.030 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 1994 | 239 | 0.030 |
Why?
|
| Personal Satisfaction | 1 | 1998 | 647 | 0.030 |
Why?
|
| Antigens, CD20 | 1 | 2014 | 199 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2016 | 855 | 0.030 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1996 | 582 | 0.030 |
Why?
|
| Feeding Behavior | 3 | 2008 | 3203 | 0.030 |
Why?
|
| Breast Neoplasms | 2 | 2011 | 21162 | 0.030 |
Why?
|
| Interleukin-4 | 2 | 2014 | 1157 | 0.030 |
Why?
|
| Informed Consent | 2 | 2001 | 1010 | 0.030 |
Why?
|
| Family Health | 1 | 1998 | 1255 | 0.030 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1994 | 329 | 0.030 |
Why?
|
| Bronchography | 1 | 2012 | 74 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2005 | 2083 | 0.030 |
Why?
|
| Oxazines | 1 | 2015 | 357 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2013 | 359 | 0.030 |
Why?
|
| Pancreatitis | 1 | 1999 | 1087 | 0.030 |
Why?
|
| Organ Specificity | 2 | 2011 | 1967 | 0.030 |
Why?
|
| HLA-DQ Antigens | 1 | 1993 | 190 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 1642 | 0.030 |
Why?
|
| Plasma Cells | 1 | 2016 | 599 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2013 | 306 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2019 | 2205 | 0.030 |
Why?
|
| CD40 Ligand | 1 | 2014 | 524 | 0.020 |
Why?
|
| Immunotherapy | 2 | 2019 | 4738 | 0.020 |
Why?
|
| Serum Albumin | 1 | 1995 | 676 | 0.020 |
Why?
|
| Lymphotoxin beta Receptor | 1 | 2011 | 26 | 0.020 |
Why?
|
| Reproducibility of Results | 3 | 2014 | 20224 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2016 | 1342 | 0.020 |
Why?
|
| Gene Library | 1 | 2014 | 1061 | 0.020 |
Why?
|
| Self Concept | 1 | 1998 | 1047 | 0.020 |
Why?
|
| Stem Cells | 1 | 2005 | 3539 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2021 | 2846 | 0.020 |
Why?
|
| Death | 1 | 2016 | 683 | 0.020 |
Why?
|
| Morpholines | 1 | 2015 | 584 | 0.020 |
Why?
|
| Silicone Gels | 1 | 2011 | 39 | 0.020 |
Why?
|
| K562 Cells | 1 | 2013 | 644 | 0.020 |
Why?
|
| Acyclovir | 1 | 1992 | 267 | 0.020 |
Why?
|
| Airway Remodeling | 1 | 2012 | 133 | 0.020 |
Why?
|
| ras Proteins | 1 | 2017 | 1058 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2020 | 1536 | 0.020 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2011 | 342 | 0.020 |
Why?
|
| Organ Transplantation | 1 | 2001 | 1177 | 0.020 |
Why?
|
| Administration, Oral | 3 | 2009 | 4039 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 2 | 1997 | 351 | 0.020 |
Why?
|
| Base Sequence | 6 | 2003 | 12422 | 0.020 |
Why?
|
| Dilatation, Pathologic | 1 | 2012 | 527 | 0.020 |
Why?
|
| Aminopyridines | 1 | 2015 | 580 | 0.020 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 1990 | 39 | 0.020 |
Why?
|
| RNA, Messenger | 4 | 1994 | 12805 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 1997 | 1735 | 0.020 |
Why?
|
| Genes, Immunoglobulin | 1 | 2011 | 286 | 0.020 |
Why?
|
| Mice, 129 Strain | 1 | 2011 | 369 | 0.020 |
Why?
|
| Hypotension | 1 | 2017 | 889 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2017 | 923 | 0.020 |
Why?
|
| Reticulin | 1 | 1990 | 19 | 0.020 |
Why?
|
| Transplantation, Isogeneic | 1 | 2010 | 249 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1992 | 1305 | 0.020 |
Why?
|
| International Agencies | 1 | 2011 | 245 | 0.020 |
Why?
|
| Splenectomy | 1 | 2012 | 392 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2017 | 2201 | 0.020 |
Why?
|
| Observation | 1 | 2011 | 311 | 0.020 |
Why?
|
| Hypergammaglobulinemia | 1 | 1989 | 71 | 0.020 |
Why?
|
| Pericarditis | 1 | 1991 | 136 | 0.020 |
Why?
|
| Skin | 1 | 2003 | 4499 | 0.020 |
Why?
|
| Antiviral Agents | 2 | 2016 | 3064 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 2000 | 5538 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 1994 | 1837 | 0.020 |
Why?
|
| Cross-Sectional Studies | 3 | 2011 | 26375 | 0.020 |
Why?
|
| Extracellular Space | 1 | 1991 | 565 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 223 | 0.020 |
Why?
|
| HLA-A2 Antigen | 1 | 2010 | 208 | 0.020 |
Why?
|
| Decision Making | 1 | 2003 | 3953 | 0.020 |
Why?
|
| Odds Ratio | 2 | 2001 | 9682 | 0.020 |
Why?
|
| Th17 Cells | 1 | 2016 | 791 | 0.020 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2009 | 94 | 0.020 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 1989 | 83 | 0.020 |
Why?
|
| Glucuronosyltransferase | 1 | 2009 | 136 | 0.020 |
Why?
|
| Antibodies, Antinuclear | 1 | 2010 | 343 | 0.020 |
Why?
|
| Interleukins | 1 | 2014 | 796 | 0.020 |
Why?
|
| Down-Regulation | 2 | 2011 | 2940 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 1992 | 1251 | 0.020 |
Why?
|
| Radiation Injuries | 2 | 2001 | 1204 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2013 | 1096 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 2013 | 992 | 0.020 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2009 | 187 | 0.020 |
Why?
|
| Exudates and Transudates | 1 | 1989 | 175 | 0.020 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 1989 | 171 | 0.020 |
Why?
|
| Hepatorenal Syndrome | 1 | 2009 | 76 | 0.020 |
Why?
|
| Bilirubin | 2 | 2002 | 438 | 0.020 |
Why?
|
| Reoperation | 2 | 2011 | 4341 | 0.020 |
Why?
|
| Life Tables | 2 | 2000 | 368 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2013 | 1479 | 0.020 |
Why?
|
| Cloning, Molecular | 2 | 2011 | 4168 | 0.020 |
Why?
|
| Leukemia, Hairy Cell | 1 | 1988 | 82 | 0.020 |
Why?
|
| Erythrocyte Count | 1 | 1988 | 157 | 0.020 |
Why?
|
| Genome, Bacterial | 1 | 2013 | 796 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 1974 | 0.020 |
Why?
|
| Drinking | 2 | 2008 | 197 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2019 | 3131 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2016 | 1967 | 0.020 |
Why?
|
| Macrocyclic Compounds | 1 | 2007 | 67 | 0.020 |
Why?
|
| Amnesia, Anterograde | 1 | 2007 | 20 | 0.020 |
Why?
|
| Kinetics | 1 | 2015 | 6333 | 0.020 |
Why?
|
| Reticulocytes | 1 | 1988 | 288 | 0.020 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 1989 | 179 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 1995 | 1180 | 0.020 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 7861 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2007 | 229 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 1975 | 1879 | 0.020 |
Why?
|
| Erythrocytes | 1 | 2016 | 2421 | 0.020 |
Why?
|
| Epitopes | 2 | 2004 | 2525 | 0.020 |
Why?
|
| Filgrastim | 1 | 2007 | 131 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 1998 | 3048 | 0.020 |
Why?
|
| Radiotherapy | 2 | 1991 | 1509 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2007 | 270 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2013 | 1561 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2016 | 2886 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2001 | 3231 | 0.020 |
Why?
|
| Diabetes Insipidus | 1 | 2007 | 144 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 1990 | 921 | 0.020 |
Why?
|
| Glioma | 1 | 2001 | 3526 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 1997 | 2906 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 2952 | 0.020 |
Why?
|
| Colitis, Ulcerative | 1 | 1998 | 1929 | 0.020 |
Why?
|
| Immunoglobulin D | 1 | 1986 | 55 | 0.020 |
Why?
|
| Hemorrhage | 3 | 2001 | 3461 | 0.020 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1987 | 187 | 0.020 |
Why?
|
| Deltaretrovirus | 1 | 1986 | 162 | 0.020 |
Why?
|
| Immunoglobulin M | 2 | 1994 | 1528 | 0.020 |
Why?
|
| Prosthesis Failure | 1 | 2011 | 1208 | 0.020 |
Why?
|
| Procarbazine | 1 | 1985 | 172 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2007 | 453 | 0.020 |
Why?
|
| Canada | 1 | 2011 | 2139 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2011 | 1727 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2017 | 2986 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2017 | 8326 | 0.020 |
Why?
|
| Phylogeny | 1 | 2013 | 2843 | 0.020 |
Why?
|
| Retroviridae Infections | 1 | 1986 | 148 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2011 | 3587 | 0.020 |
Why?
|
| Interferon-gamma | 2 | 2010 | 3164 | 0.020 |
Why?
|
| Myeloid Cells | 1 | 2010 | 832 | 0.010 |
Why?
|
| Gene Amplification | 1 | 1989 | 1090 | 0.010 |
Why?
|
| Intelligence | 1 | 2010 | 929 | 0.010 |
Why?
|
| Tissue and Organ Procurement | 1 | 1993 | 986 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 2830 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 7463 | 0.010 |
Why?
|
| Interferon Type I | 1 | 1988 | 569 | 0.010 |
Why?
|
| Sick Role | 1 | 2005 | 229 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 1991 | 1410 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 2009 | 1364 | 0.010 |
Why?
|
| Receptors, Transferrin | 1 | 2005 | 300 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2010 | 1532 | 0.010 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2007 | 390 | 0.010 |
Why?
|
| DNA | 3 | 1985 | 7211 | 0.010 |
Why?
|
| Pyridines | 1 | 2015 | 2889 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 4357 | 0.010 |
Why?
|
| Mastectomy | 1 | 2011 | 1851 | 0.010 |
Why?
|
| Antibodies, Neutralizing | 1 | 2013 | 2006 | 0.010 |
Why?
|
| Chromosomes, Human, X | 1 | 2005 | 320 | 0.010 |
Why?
|
| Fibrosis | 1 | 1990 | 2077 | 0.010 |
Why?
|
| Neprilysin | 1 | 1986 | 487 | 0.010 |
Why?
|
| Blood Proteins | 1 | 2008 | 1186 | 0.010 |
Why?
|
| Bacterial Infections | 3 | 1997 | 1397 | 0.010 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 1986 | 547 | 0.010 |
Why?
|
| Molecular Sequence Data | 4 | 2004 | 17626 | 0.010 |
Why?
|
| Preoperative Care | 1 | 1991 | 2258 | 0.010 |
Why?
|
| Breast | 1 | 2011 | 1975 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2008 | 2079 | 0.010 |
Why?
|
| Health Status | 2 | 2009 | 4094 | 0.010 |
Why?
|
| Autoantibodies | 1 | 2010 | 2126 | 0.010 |
Why?
|
| Therapeutic Equivalency | 1 | 2002 | 134 | 0.010 |
Why?
|
| Collagen | 1 | 1990 | 2646 | 0.010 |
Why?
|
| Pandemics | 1 | 2021 | 8753 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1986 | 1438 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2013 | 2544 | 0.010 |
Why?
|
| Marriage | 1 | 2003 | 352 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 2011 | 1959 | 0.010 |
Why?
|
| Endothelium | 1 | 2003 | 768 | 0.010 |
Why?
|
| Blood Coagulation | 1 | 1987 | 1161 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2014 | 7145 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 1994 | 3838 | 0.010 |
Why?
|
| Ascites | 1 | 2002 | 338 | 0.010 |
Why?
|
| Gene Expression Regulation | 2 | 2005 | 11918 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2009 | 4142 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 1992 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2001 | 9198 | 0.010 |
Why?
|
| Musculoskeletal Diseases | 1 | 2006 | 601 | 0.010 |
Why?
|
| Life Change Events | 1 | 2005 | 962 | 0.010 |
Why?
|
| Sex Characteristics | 2 | 2003 | 2660 | 0.010 |
Why?
|
| Amygdala | 1 | 2007 | 1382 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 9562 | 0.010 |
Why?
|
| Biochemical Phenomena | 1 | 1959 | 59 | 0.010 |
Why?
|
| Citrates | 1 | 1959 | 134 | 0.010 |
Why?
|
| Cell Line | 1 | 2013 | 15597 | 0.010 |
Why?
|
| Observer Variation | 1 | 2005 | 2623 | 0.010 |
Why?
|
| Citric Acid | 1 | 1959 | 124 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2004 | 1337 | 0.010 |
Why?
|
| Rats | 5 | 1998 | 23835 | 0.010 |
Why?
|
| Rickets | 1 | 1959 | 70 | 0.010 |
Why?
|
| Receptors, Purinergic P1 | 1 | 1998 | 108 | 0.010 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2002 | 495 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1978 | 305 | 0.010 |
Why?
|
| Antigens, Nuclear | 1 | 1998 | 183 | 0.010 |
Why?
|
| Thalassemia | 1 | 1998 | 267 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 9510 | 0.010 |
Why?
|
| Government Regulation | 1 | 2002 | 525 | 0.010 |
Why?
|
| Lung | 1 | 2016 | 10089 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 4588 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2003 | 3102 | 0.010 |
Why?
|
| Acinetobacter Infections | 1 | 1997 | 73 | 0.010 |
Why?
|
| Prevalence | 1 | 2014 | 15872 | 0.010 |
Why?
|
| Genome, Human | 1 | 2009 | 4450 | 0.010 |
Why?
|
| Sterilization | 1 | 1997 | 132 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 1998 | 628 | 0.010 |
Why?
|
| Taste | 2 | 1974 | 190 | 0.010 |
Why?
|
| Drug Contamination | 1 | 1997 | 151 | 0.010 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2000 | 605 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 2001 | 1696 | 0.010 |
Why?
|
| Quinine | 1 | 1975 | 51 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 11120 | 0.010 |
Why?
|
| Tuberculosis | 1 | 1988 | 2029 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2002 | 1476 | 0.010 |
Why?
|
| Biological Availability | 1 | 1996 | 392 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1998 | 1705 | 0.010 |
Why?
|
| Bacterial Capsules | 1 | 1996 | 247 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2002 | 1397 | 0.010 |
Why?
|
| Research Design | 1 | 2011 | 6210 | 0.010 |
Why?
|
| Drinking Behavior | 1 | 1975 | 103 | 0.010 |
Why?
|
| Narcotics | 1 | 1997 | 334 | 0.010 |
Why?
|
| Heart Failure | 2 | 1991 | 11858 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 3712 | 0.010 |
Why?
|
| Hippocampus | 1 | 2007 | 3784 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2003 | 2429 | 0.010 |
Why?
|
| Bacterial Vaccines | 1 | 1996 | 400 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1998 | 1905 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 1975 | 584 | 0.010 |
Why?
|
| Marijuana Abuse | 1 | 1997 | 410 | 0.010 |
Why?
|
| Parity | 1 | 1996 | 938 | 0.010 |
Why?
|
| Reflex | 1 | 1974 | 375 | 0.010 |
Why?
|
| Emotions | 1 | 2005 | 2768 | 0.010 |
Why?
|
| Social Adjustment | 1 | 1995 | 636 | 0.010 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1998 | 1163 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1993 | 510 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 13423 | 0.010 |
Why?
|
| Avoidance Learning | 1 | 1974 | 249 | 0.010 |
Why?
|
| Respiratory Insufficiency | 1 | 2001 | 1241 | 0.010 |
Why?
|
| Concanavalin A | 1 | 1991 | 190 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2001 | 1890 | 0.010 |
Why?
|
| Cocaine | 1 | 1997 | 960 | 0.010 |
Why?
|
| Vaccines, Synthetic | 1 | 1994 | 622 | 0.010 |
Why?
|
| Benzodiazepines | 1 | 1997 | 1139 | 0.010 |
Why?
|
| Eating | 2 | 1974 | 1541 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2001 | 2337 | 0.010 |
Why?
|
| Dactinomycin | 1 | 1991 | 305 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1991 | 826 | 0.010 |
Why?
|
| Vitamins | 1 | 1959 | 1637 | 0.010 |
Why?
|
| Parenteral Nutrition, Total | 1 | 1991 | 304 | 0.010 |
Why?
|
| Amphotericin B | 1 | 1990 | 143 | 0.010 |
Why?
|
| Body Water | 1 | 1991 | 340 | 0.010 |
Why?
|
| Demography | 1 | 1995 | 1642 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 1994 | 991 | 0.010 |
Why?
|
| Stomach | 1 | 1974 | 703 | 0.010 |
Why?
|
| Taq Polymerase | 1 | 1989 | 20 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 1998 | 1389 | 0.010 |
Why?
|
| Probability | 1 | 1995 | 2482 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2013 | 23631 | 0.010 |
Why?
|
| Anxiety | 1 | 2005 | 4677 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2001 | 2721 | 0.010 |
Why?
|
| Hematocrit | 1 | 1990 | 625 | 0.010 |
Why?
|
| Algorithms | 1 | 2010 | 14154 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1989 | 417 | 0.010 |
Why?
|
| Erythrocyte Transfusion | 1 | 1994 | 575 | 0.000 |
Why?
|
| Mycobacterium avium | 1 | 1988 | 29 | 0.000 |
Why?
|
| Mass Screening | 1 | 2005 | 5451 | 0.000 |
Why?
|
| Proto-Oncogenes | 1 | 1989 | 322 | 0.000 |
Why?
|
| Electrophysiology | 1 | 1991 | 1266 | 0.000 |
Why?
|
| Body Weight | 2 | 1991 | 4629 | 0.000 |
Why?
|
| Artificial Intelligence | 1 | 2003 | 2661 | 0.000 |
Why?
|
| False Negative Reactions | 1 | 1989 | 575 | 0.000 |
Why?
|
| Cell Line, Tumor | 1 | 2004 | 17135 | 0.000 |
Why?
|
| Macromolecular Substances | 1 | 1990 | 1435 | 0.000 |
Why?
|
| Interviews as Topic | 1 | 1995 | 2740 | 0.000 |
Why?
|
| Oligonucleotides | 1 | 1990 | 564 | 0.000 |
Why?
|
| False Positive Reactions | 1 | 1989 | 962 | 0.000 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2005 | 4641 | 0.000 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 1989 | 481 | 0.000 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 1986 | 131 | 0.000 |
Why?
|
| Alcoholism | 1 | 1997 | 1982 | 0.000 |
Why?
|
| Logistic Models | 1 | 2001 | 13323 | 0.000 |
Why?
|
| Cardiovascular Diseases | 1 | 2011 | 15649 | 0.000 |
Why?
|
| Motor Activity | 1 | 1975 | 2720 | 0.000 |
Why?
|
| Vitamin D | 1 | 1959 | 3310 | 0.000 |
Why?
|
| Kidney Diseases | 1 | 1996 | 2103 | 0.000 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1988 | 1355 | 0.000 |
Why?
|
| Hematopoietic System | 1 | 1985 | 110 | 0.000 |
Why?
|
| Blood Coagulation Disorders | 1 | 1988 | 350 | 0.000 |
Why?
|
| Gene Rearrangement | 1 | 1989 | 1139 | 0.000 |
Why?
|
| Surface Properties | 1 | 1986 | 1167 | 0.000 |
Why?
|
| Nuclear Proteins | 1 | 1998 | 5800 | 0.000 |
Why?
|
| Lymphoid Tissue | 1 | 1985 | 446 | 0.000 |
Why?
|
| Palliative Care | 1 | 1998 | 3643 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1998 | 13020 | 0.000 |
Why?
|
| Anemia | 1 | 1991 | 1519 | 0.000 |
Why?
|
| Pregnancy | 1 | 2001 | 30200 | 0.000 |
Why?
|
| Echocardiography | 1 | 1991 | 5044 | 0.000 |
Why?
|
| Ventricular Function, Left | 1 | 1991 | 3941 | 0.000 |
Why?
|
| Electrocardiography | 1 | 1991 | 6409 | 0.000 |
Why?
|
| Liver Neoplasms | 1 | 1990 | 4365 | 0.000 |
Why?
|
| Water Deprivation | 1 | 1974 | 19 | 0.000 |
Why?
|
| Saccharin | 1 | 1974 | 20 | 0.000 |
Why?
|
| Apomorphine | 1 | 1974 | 150 | 0.000 |
Why?
|
| Fistula | 1 | 1974 | 213 | 0.000 |
Why?
|
| Pharynx | 1 | 1974 | 436 | 0.000 |
Why?
|
| Intestine, Small | 1 | 1974 | 1218 | 0.000 |
Why?
|